Please assess the completion status of the following clinical trial:

Trial Title: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible for inclusion in the study:~* Patients diagnosed with neovascular AMD, DME or macular edema secondary to RVO undergoing anti-VEGF injections in both eyes.~* \> 18 years old~* Able to provide signed written consent prior to participation in any study-related procedures.~Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study:~* Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days prior to Screening and throughout the study period (systemic mast cell stabilizers are allowed, and systemic antihistamines are permitted)~* Use of any topical prescription ophthalmic medications (including cyclosporine \[Restasis®, Cequa®\] or topical lifitegrast \[Xiidra®\], steroids, nonsteroidal anti- inflammatory drugs \[NSAIDs\]within 7 days or during study period~* Participation in any drug or device clinical investigation within 30 days prior to study entry and/or during the study period.~* Anterior chamber cells present at time of enrollment~* History of cauterization of the punctum~* Any punctum inflammation or dacryocystitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextenza (Type: EXPERIMENTAL): Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
- Topical Corticosteroids (Type: ACTIVE_COMPARATOR): Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).

Based on this trial design, predict the completion outcome and termination type (if applicable).